It is in the cards, and thus should come as no big surprise, that the pharmaceutical company Biogen is very likely to receive the European thumbs-down for its Alzheimer's drug, Aduhelm (aducanumab).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu, Coloplast and GN helped by relaxation of China's covid policy
The three firms, which all have production facilities in the country, appear to be benefitting from the relaxation of China’s zero-tolerance Covid-19 policy.
Sonova completes Hysound Group acquisition, strengthens presence in China
The hearing aid giant now owns over 200 hearing clinics in China.
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Top news from MedWatch this week
Miss anything?
Project Director of CMC & Device, Zealand Pharma A/S / 1801 
Head of Regulatory Affairs Danmark 
Quality Assurance Specialist (QAS) in dietary supplements 
Principal Systems Engineer 
External Manufacturing Leads 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Laboratory assistants for an exciting QC department 
Chief consultant for Dansk Erhvervs Health and life science 
Research Scientist (maternity cover) 
Supply Chain Manager 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market